Related Experiment Video
Updated: May 14, 2026
Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting
Published on: September 25, 2012
Targeting Glioblastoma Stem Cells: Therapeutic Strategies and Clinical Perspectives
Harikrishna Reddy Rachamala1, Sonia Devi Lourembam2, Debabrata Mukhopadhyay1
1Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA.
Abstract:
With limited therapeutic progress despite aggressive multimodal treatment, glioblastoma (GBM) remains one of the deadliest primary brain tumors. Emerging evidence suggests that GSCs are key drivers of tumor initiation, intratumoral heterogeneity, therapeutic resistance, and recurrence. GSCs retain self-renewal capacity, multilineage differentiation potential, and remarkable plasticity, enabling them to adapt to diverse microenvironmental cues. These properties are upheld by dysregulated developmental and oncogenic signaling pathways, including Notch, Wnt/β-catenin, Hedgehog, PI3K/AKT/mTOR, and STAT3, as well as epigenetic and metabolic reprogramming. In addition, dedicated niches such as hypoxic and perivascular microenvironments critically support GSC maintenance and immune evasion. In this review, we summarize the current understanding of the molecular pathways governing GSC biology, examine their interactions with the tumor microenvironment, and discuss emerging therapeutic strategies targeting GSCs, including pathway inhibition, differentiation therapy, immunotherapy, and nanomedicine-based drug delivery. We highlight key challenges and future directions for translating GSC-targeted approaches into effective clinical interventions for GBM.
Insights
Glioblastoma stem cells drive tumor growth and resistance. Targeting these cells and their microenvironment offers new therapeutic strategies for this deadly brain cancer.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Molecular Oncology
Background:
- Glioblastoma (GBM) is a highly lethal brain tumor with poor therapeutic outcomes.
- Glioblastoma stem cells (GSCs) are implicated in tumor initiation, heterogeneity, and treatment resistance.
Purpose of the Study:
- To review the molecular pathways governing GSC biology.
- To examine GSC interactions with the tumor microenvironment.
- To discuss emerging therapeutic strategies targeting GSCs.
Main Methods:
- Literature review of molecular pathways in GSC biology.
- Analysis of GSC interactions with tumor microenvironments (hypoxic, perivascular).
- Summary of therapeutic strategies including pathway inhibition, differentiation therapy, immunotherapy, and nanomedicine.
Main Results:
- GSC properties are regulated by signaling pathways (Notch, Wnt, Hedgehog, PI3K/AKT/mTOR, STAT3) and epigenetic/metabolic changes.
- Tumor microenvironments critically support GSC maintenance and immune evasion.
- Multiple therapeutic strategies targeting GSCs are under investigation.
Conclusions:
- Understanding GSC biology and microenvironment is crucial for GBM treatment.
- Targeting GSCs holds promise for improving clinical outcomes in glioblastoma.
- Further research is needed to translate GSC-targeted therapies into effective clinical practice.
